TD Cowen lowered the firm’s price target on PTC Therapeutics to $30 from $32 and keeps a Market Perform rating on the shares. The firm said they posted an inline report and with challenges to the topline emerging, regulatory execution in FA and across the pipeline will be key in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics Q4 and Fiscal Year-End Financial Update Call
- PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- SHAREHOLDER ALERT: Potential Recovery for PTC Therapeutics, Inc. (PTCT) Investors
- PTCT Earnings this Week: How Will it Perform?
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
